PKM-02
Hemoglobinopathies (e.g., via HSCT enhancement)
Pre-clinicalActive
Key Facts
About PK MED
PK MED is a privately held, venture-backed French biotech developing a proprietary platform of tailor-designed, injectable, biodegradable micro-implants for localized drug delivery and cell homing. Its lead program, PKM-01 for gout flare, has received FDA clearance to initiate clinical development directly with a Phase 2 study via a 505(b)(2) pathway. The company's strategy leverages known drugs in novel delivery systems to create faster-acting, safer therapies with potentially abbreviated development timelines in areas with significant patient need and limited treatment options.
View full company profile